Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells that can invade tissues and metastasize to distant organs.
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
FDA approved iberdomide (Zenbexus) with daratumumab and dexamethasone for pretreated myeloma. The EXCALIBER-RRMM trial showed a 41% MRD-negative complete response rate vs 21%.
Servier agreed to acquire Day One for $2.5B, gaining an approved childhood brain tumor drug and pipeline assets. SCRI and MSD launched a collaboration to expand community oncology trial access, while Recursion took full ownership of REC-102 as Nvidia and Novo exited.
Perspective Therapeutics plans May 2026 analyst event, Q1 results, and conference appearances. The radiopharmaceutical firm is advancing 212Pb-based therapies in Phase 1/2a trials and expanding facilities.
First Ascent Biomedical opened a CLIA- and CAP-certified FPM lab in Miami, testing FDA-approved drugs on patient tumor cells with results in ~10 days. Sponsored testing is available for eligible Florida residents and colorectal cancer patients.
Flow-based human tissue models show stronger T-cell activity than static cultures, with blinatumomab inducing significant B-cell killing and cytokine release. Sartorius has introduced a 96-well multi-organ tox plate for drug toxicity testing, while in vitro systems are increasingly used as new approach methodologies to complement animal models.
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Novartis marks 30 years since its 1996 merger, citing advances in targeted therapy, cell therapy, gene therapy, and malaria. It also named a Levant Country President and won two clinical research awards in Saudi Arabia.
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778173 |
Three-Dimensional Molds Based on Radiological imagEs in Patients With Cancer: the DIRECT Trial |
RECRUITING | NA |
| NCT07776964 |
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) |
NOT_YET_RECRUITING | NA |
| NCT07776704 |
Indirect Calorimetry-Guided Parenteral Nutrition Prescribing in Oncology Patients |
RECRUITING | NA |
| NCT07776587 |
Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients |
NOT_YET_RECRUITING | NA |
| NCT07773454 |
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07771712 |
Combined Pectoserratus and Superficial Cervical Plexus Block Versus Local Infiltration for Chemoport Implantation |
COMPLETED | NA |
| NCT07769931 |
Effect of Pecha Kucha-Based Education on Symptom Management and Quality of Life in Patients Receiving Chemotherapy |
RECRUITING | NA |
| NCT07767448 |
Characterization of Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events |
NOT_YET_RECRUITING | NA |
| NCT07766252 |
CCHW-delivered CFH-based Cancer Prevention Program Among Chinese Americans |
COMPLETED | NA |
| NCT07765069 |
Positioning in RT - Supine vs. Upright |
NOT_YET_RECRUITING |
